Lice Buyer's Guide: Treatment Product Reviews Go Now

Aczone

Generic Name: dapsone
Dosage Form: gel

Indications and Usage for Aczone

Aczone® Gel, 5%, is indicated for the topical treatment of acne vulgaris.

Aczone Dosage and Administration

For topical use only. Not for oral, ophthalmic, or intravaginal use.

After the skin is gently washed and patted dry, apply approximately a pea-sized amount of Aczone® Gel, 5%, in a thin layer to the acne affected areas twice daily. Rub in Aczone® Gel, 5%, gently and completely. Aczone® Gel, 5%, is gritty with visible drug substance particles. Wash hands after application of Aczone® Gel, 5%.

Slideshow: Lifestyle Lessons - 9 Tips For Managing Type 2 Diabetes

If there is no improvement after 12 weeks, treatment with Aczone® Gel, 5%, should be reassessed.

Dosage Forms and Strengths

Aczone® (dapsone) Gel, 5%, is supplied in the following size tubes:

  • Professional Sample: 3 gram laminate tube
  • Commercially: 30, 60, and 90 gram laminate tubes

Contraindications

None.

Warnings and Precautions

Hematological Effects

Oral dapsone treatment has produced dose-related hemolysis and hemolytic anemia. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are more prone to hemolysis with the use of certain drugs. G6PD deficiency is most prevalent in populations of African, South Asian, Middle Eastern, and Mediterranean ancestry.

There was no evidence of clinically relevant hemolysis or anemia in patients treated with Aczone® Gel, 5%, including patients who were G6PD deficient. Some subjects with G6PD deficiency using Aczone® Gel developed laboratory changes suggestive of mild hemolysis.

If signs and symptoms suggestive of hemolytic anemia occur, Aczone® Gel, 5% should be discontinued. Aczone® Gel, 5% should not be used in patients who are taking oral dapsone or antimalarial medications because of the potential for hemolytic reactions. Combination of Aczone® Gel, 5%, with trimethoprim/sulfamethoxazole (TMP/SMX) may increase the likelihood of hemolysis in patients with G6PD deficiency.

Peripheral Neuropathy

Peripheral neuropathy (motor loss and muscle weakness) has been reported with oral dapsone treatment. No events of peripheral neuropathy were observed in clinical trials with topical Aczone® Gel, 5% treatment.

Skin

Skin reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarlatiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria) have been reported with oral dapsone treatment. These types of skin reactions were not observed in clinical trials with topical Aczone® Gel, 5% treatment.

Adverse Reactions

Clinical Studies Experience

Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Serious adverse reactions reported in patients treated with Aczone® Gel, 5%, during clinical trials included but were not limited to the following:

  • Nervous system/Psychiatric – Suicide attempt, tonic clonic movements.
  • Gastrointestinal – Abdominal pain, severe vomiting, pancreatitis.
  • Other – Severe pharyngitis

In the clinical trials, a total of 12 out of 4032 patients were reported to have depression (3 of 1660 treated with vehicle and 9 of 2372 treated with Aczone® Gel, 5%). Psychosis was reported in 2 of 2372 patients treated with Aczone® Gel, 5%, and in 0 of 1660 patients treated with vehicle.

Combined contact sensitization/irritation studies with Aczone® Gel, 5%, in 253 healthy subjects resulted in at least 3 subjects with moderate erythema. Aczone® Gel, 5%, did not induce phototoxicity or photoallergy in human dermal safety studies.

Aczone® Gel, 5%, was evaluated for 12 weeks in four controlled studies for local cutaneous events in 1819 patients. The most common events reported from these studies include oiliness/peeling, dryness, and erythema. These data are shown by severity in Table 1 below.

Table 1 – Application Site Adverse Reactions by Maximum Severity
Aczone®
(N=1819)
Vehicle
(N=1660)
Application Site Event Mild Moderate Severe Mild Moderate Severe
Erythema 9% 5% <1% 9% 6% <1%
Dryness 14% 3% <1% 14% 4% <1%
Oiliness/Peeling 13% 6% <1% 15% 6% <1%

The adverse reactions occurring in at least 1% of patients in either arm in the four vehicle controlled studies are presented in Table 2.

Table 2 – Adverse Reactions Occurring in at Least 1% of Patients

NOS = Not otherwise specified

Aczone®
N=1819
Vehicle
N=1660
Application Site Reaction NOS 18% 20%
Application Site Dryness 16% 17%
Application Site Erythema 13% 14%
Application Site Burning 1% 2%
Application Site Pruritus 1% 1%
Pyrexia 1% 1%
Nasopharyngitis 5% 6%
Upper Respiratory Tract Inf. NOS 3% 3%
Sinusitis NOS 2% 1%
Influenza 1% 1%
Pharyngitis 2% 2%
Cough 2% 2%
Joint Sprain 1% 1%
Headache NOS 4% 4%

One patient treated with Aczone® Gel in the clinical trials had facial swelling which led to discontinuation of medication.

In addition, 486 patients were evaluated in a 12 month safety study. The adverse event profile in this study was consistent with that observed in the vehicle-controlled studies.

Experience with Oral Use of Dapsone

Although not observed in the clinical trials with Aczone® Gel (topical dapsone) serious adverse reactions have been reported with oral use of dapsone, including agranulocytosis, hemolytic anemia, peripheral neuropathy (motor loss and muscle weakness), and skin reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarlatiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria).

Drug Interactions

Trimethoprim-Sulfamethoxazole

A drug-drug interaction study evaluated the effect of the use of Aczone® Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim-sulfamethoxazole (TMP/SMX). During co-administration, systemic levels of TMP and SMX were essentially unchanged. However, levels of dapsone and its metabolites increased in the presence of TMP/SMX. Systemic exposure (AUC0-12) of dapsone and N-acetyl-dapsone (NAD) were increased by about 40% and 20% respectively in the presence of TMP/SMX. Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of TMP/SMX. Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX.

Topical Benzoyl Peroxide

Topical application of Aczone® Gel followed by benzoyl peroxide in subjects with acne vulgaris resulted in a temporary local yellow or orange discoloration of the skin and facial hair (reported by 7 out of 95 subjects in a clinical study) with resolution in 4 to 57 days.

Drug Interactions with Oral Dapsone

Certain concomitant medications (such as rifampin, anticonvulsants, St. John's wort) may increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis. With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions.

USE IN SPECIFIC POPULATIONS

Pregnancy

Teratogenic Effects: Pregnancy Category C

There are no adequate and well controlled studies in pregnant women. Dapsone has been shown to have an embryocidal effect in rats and rabbits when administered orally in doses of 75 mg/kg/day and 150 mg/kg/day (approximately 800 and 500 times the systemic exposure observed in human females as a result of use of the maximum recommended topical dose, based on AUC comparisons), respectively. These effects were probably secondary to maternal toxicity. Aczone® Gel, 5%, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Although systemic absorption of dapsone following topical application of Aczone® Gel, 5%, is minimal relative to oral dapsone administration, it is known that dapsone is excreted in human milk. Because of the potential for oral dapsone to cause adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue Aczone® Gel, 5%, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and efficacy was evaluated in 1169 children aged 12-17 years old treated with Aczone® Gel, 5%, in the clinical studies. The adverse event rate for Aczone® Gel, 5%, was similar to the vehicle control group. Safety and efficacy was not studied in pediatric patients less than 12 years of age, therefore Aczone® Gel, 5%, is not recommended for use in this age group.

Geriatric Use

Clinical studies of Aczone® Gel, 5%, did not include sufficient number of patients aged 65 and over to determine whether they respond differently from younger patients.

G6PD Deficiency

Aczone® Gel, 5% and vehicle were evaluated in a randomized, double-blind, cross-over design clinical study of 64 patients with G6PD deficiency and acne vulgaris. Subjects were Black (88%), Asian (6%), Hispanic (2%) or of other racial origin (5%). Blood samples were taken at Baseline, Week 2, and Week 12 during both vehicle and Aczone® Gel, 5% treatment periods. There were 56 out of 64 subjects who had a Week 2 blood draw and applied at least 50% of treatment applications. Table 3 contains results from testing of relevant hematology parameters for these two treatment periods. Aczone® Gel was associated with a 0.32 g/dL drop in hemoglobin after two weeks of treatment, but hemoglobin levels generally returned to baseline levels at Week 12.

Table 3 – Mean Hemoglobin, Bilirubin, and Reticulocyte Levels in Acne Subjects with G6PD Deficiency in Aczone®/Vehicle Cross-Over Study
Aczone® Vehicle
N Mean N Mean
Hemoglobin (g/dL) Pre-treatment 53 13.44 56 13.36
2 weeks 53 13.12 55 13.34
12 weeks 50 13.42 50 13.37
Bilirubin (mg/dL) Pre-treatment 54 0.58 56 0.55
2 weeks 53 0.65 55 0.56
12 weeks 50 0.61 50 0.62
Reticulocytes (%) Pre-treatment 53 1.30 55 1.34
2 weeks 53 1.51 55 1.34
12 weeks 50 1.48 50 1.41

There were no changes from baseline in haptoglobin or lactate dehydrogenase during Aczone® or vehicle treatment at either the 2-week or 12-week time point.

The proportion of subjects who experienced decreases in hemoglobin ≥1 g/dL was similar between Aczone® Gel, 5% and vehicle treatment (8 of 58 subjects had such decreases during Aczone® treatment compared to 7 of 56 subjects during vehicle treatment among subjects with at least one on-treatment hemoglobin assessment). Subgroups based on gender, race, or G6PD enzyme activity did not display any differences in laboratory results from the overall study group. There was no evidence of clinically significant hemolytic anemia in this study. Some of these subjects developed laboratory changes suggestive of mild hemolysis.

Overdosage

Aczone® Gel, 5%, is not for oral use. If oral ingestion occurs, medical advice should be sought.

Aczone Description

Aczone® Gel, 5%, contains dapsone, a sulfone, in an aqueous gel base for topical dermatologic use. Aczone® Gel, 5% is a gritty translucent material with visible drug substance particles. Chemically, dapsone has an empirical formula of C12H12N2O2S. It is a white, odorless crystalline powder that has a molecular weight of 248. Dapsone's chemical name is 4,4'-diaminodiphenylsulfone and its structural formula is:

Each gram of Aczone® Gel, 5%, contains 50 mg of dapsone, USP, in a gel of carbomer homopolymer type C; diethylene glycol monoethyl ether, NF; methylparaben, NF; sodium hydroxide, NF; and purified water, USP.

Aczone - Clinical Pharmacology

Mechanism of Action

The mechanism of action of dapsone gel in treating acne vulgaris is not known.

Pharmacokinetics

An open-label study compared the pharmacokinetics of dapsone after Aczone® Gel, 5%, (110 ± 60 mg/day) was applied twice daily (~BSA 22.5%) for 14 days (n=18) with a single 100 mg dose of oral dapsone administered to a subgroup of patients (n=10) in a crossover design. On Day 14 the mean dapsone AUC0-24h was 415 ± 224 ng•h/mL for Aczone® Gel, 5%, whereas following a single 100 mg dose of oral dapsone the AUC0-infinity was 52,641 ± 36,223 ng•h/mL. Exposure after the oral dose of 100 mg dapsone was approximately 100 times greater than after the topical Aczone® Gel, 5% dose, twice a day.

In a long-term safety study of Aczone® Gel, 5% treatment, periodic blood samples were collected up to 12 months to determine systemic exposure of dapsone and its metabolites in approximately 500 patients. Based on the measurable dapsone concentrations from 408 patients (M=192, F=216), obtained at month 3, neither gender, nor race appeared to affect the pharmacokinetics of dapsone. Similarly, dapsone exposures were approximately the same between the age groups of 12-15 years (N=155) and those greater than or equal to 16 years (N=253). There was no evidence of increasing systemic exposure to dapsone over the study year in these patients.

Microbiology

In Vivo Activity: No microbiology or immunology studies were conducted during dapsone gel clinical trials.

Drug Resistance: No dapsone resistance studies were conducted during dapsone gel clinical trials. Because no microbiology studies were done, there are no data available as to whether dapsone treatment may have resulted in decreased susceptibility of Propionibacterium acnes, an organism associated with acne, to other antimicrobials that may be used to treat acne. Therapeutic resistance to dapsone has been reported for Mycobacterium leprae, when patients have been treated with oral dapsone.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

Dapsone was not mutagenic in a bacterial reverse mutation assay (Ames test) using S. typhimurium and E. coli, with and without metabolic activation and was negative in a micronucleus assay conducted in mice. Dapsone increased both numerical and structural aberrations in a chromosome aberration assay conducted with Chinese hamster ovary (CHO) cells.

Dapsone was not carcinogenic to rats when orally administered to females for 92 weeks or males for 100 weeks at dose levels up to 15 mg/kg/day (approximately 160 times the systemic exposure observed in human males and 300 times the systemic exposure observed in human females as a result of use of the maximum recommended topical dose, based on AUC comparisons).

No evidence of potential to induce carcinogenicity was obtained in a dermal study in which dapsone gel was topically applied to Tg.AC transgenic mice for approximately 26 weeks. Dapsone concentrations of 3%, 5%, and 10% were evaluated; 3% material was judged to be the maximum tolerated dosage.

Aczone® Gel, 5%, did not increase the rate of formation of ultraviolet light-induced skin tumors when topically applied to hairless mice in a 12-month photocarcinogenicity study.

The effects of dapsone on fertility and general reproduction performance were assessed in male and female rats following oral (gavage) dosing. Dapsone reduced sperm motility at dosages of 3 mg/kg/day or greater (approximately 17 times the systemic exposure observed in human males as a result of use of the maximum recommended topical dose, based on AUC comparisons). The mean numbers of embryo implantations and viable embryos were significantly reduced in untreated females mated with males that had been dosed at 12 mg/kg/day or greater (approximately 70 times the systemic exposure observed in human males as a result of use of the maximum recommended topical dose, based on AUC comparisons), presumably due to reduced numbers or effectiveness of sperm, indicating impairment of fertility. Dapsone had no effect on male fertility at dosages of 2 mg/kg/day or less (approximately 13 times the systemic exposure observed in human males as a result of use of the maximum recommended topical dose, based on AUC comparisons). When administered to female rats at a dosage of 75 mg/kg/day (approximately 800 times the systemic exposure observed in human females as a result of use of the maximum recommended topical dose, based on AUC comparisons) for 15 days prior to mating and for 17 days thereafter, dapsone reduced the mean number of implantations, increased the mean early resorption rate, and reduced the mean litter size. These effects were probably secondary to maternal toxicity.

Dapsone was assessed for effects on perinatal/postnatal pup development and postnatal maternal behavior and function in a study in which dapsone was orally administered to female rats daily beginning on the seventh day of gestation and continuing until the twenty-seventh day postpartum. Maternal toxicity (decreased body weight and food consumption) and developmental effects (increase in stillborn pups and decreased pup weight) were seen at a dapsone dose of 30 mg/kg/day (approximately 500 times the systemic exposure observed in human females as a result of use of the maximum recommended topical dose, based on AUC comparisons). No effects were observed on the viability, physical development, behavior, learning ability, or reproductive function of surviving pups.

Clinical Studies

Two randomized, double-blind, vehicle-controlled, clinical studies were conducted to evaluate Aczone® Gel, 5%, for the treatment of patients with acne vulgaris (N=1475 and 1525). The studies were designed to enroll patients 12 years of age and older with 20 to 50 inflammatory and 20 to 100 non-inflammatory lesions at baseline. In these studies patients applied either Aczone® Gel, 5%, or vehicle control twice daily for up to 12 weeks. Efficacy was evaluated in terms of success on the Global Acne Assessment Score (no or minimal acne) and in the percent reduction in inflammatory, non-inflammatory, and total lesions.

The Global Acne Assessment Score was a 5-point scale as follows:

0 None: no evidence of facial acne vulgaris
1 Minimal: few non-inflammatory lesions (comedones) are present; a few inflammatory lesions (papules/pustules) may be present
2 Mild: several to many non-inflammatory lesions (comedones) are present; a few inflammatory lesions (papules/pustules) are present
3 Moderate: many non-inflammatory (comedones) and inflammatory lesions (papules/pustules) are present; no nodulo-cystic lesions are allowed
4 Severe: significant degree of inflammatory disease; papules/pustules are a predominant feature; a few nodulo-cystic lesions may be present; comedones may be present.

The success rates on the Global Acne Assessment Score (no or minimal acne) at Week 12 are presented in Table 4.

Table 4 - Success (No or Minimal Acne) on the Global Acne Assessment Score at Week 12

*Analysis excludes subjects classified with minimal acne at baseline

Study 1* Study 2*
Aczone®
N=699
Vehicle
N=687
Aczone®
N=729
Vehicle
N=738
Subjects with No or Minimal Acne 291 (42%) 223 (32%) 253 (35%) 206 (28%)

Table 5 presents the mean percent reduction in inflammatory, non-inflammatory, and total lesions from baseline to Week 12.

Table 5 - Percent Reduction in Lesions from Baseline to Week 12
Study 1 Study 2
Aczone®
N=745
Vehicle
N=740
Aczone®
N=761
Vehicle
N=764
Inflammatory 46% 42% 48% 40%
Non-Inflammatory 31% 24% 30% 21%
Total 38% 32% 37% 29%

The clinical studies enrolled about equal proportions of male and female subjects. Female patients tended to have greater percent reductions in lesions and greater success on the Global Acne Assessment Score than males. The breakdown by race in the clinical studies was about 73% Caucasian, 14% Black, 9% Hispanic, and 2% Asian. Efficacy results were similar across the racial subgroups.

How Supplied/Storage and Handling

Aczone® (dapsone) Gel, 5%, is supplied in the following size tubes:

Professional Sample
5% NDC 0023-3670-03
3 gram laminate tube

Commercially Available as:
5% NDC 0023-3670-30
30 gram laminate tube

5% NDC 0023-3670-60
60 gram laminate tube

5% NDC 0023-3670-90
90 gram laminate tube

KEEP OUT OF THE REACH OF CHILDREN LESS THAN 12 YEARS OLD.

Storage conditions:
Store at controlled room temperature, 20°-25°C (68°-77°F), excursions permitted to 15°-30ºC (59°-86ºF). Protect from freezing.

Patient Counseling Information

See FDA-Approved Patient Labeling (17.2)

Information for Patients

  1. Patients should use Aczone® Gel, 5%, as directed by the physician. Aczone® Gel, 5%, is for external topical use only. Aczone® Gel, 5%, is not for oral, ophthalmic or intravaginal use.
  2. Patients should not use this medication for any disorder other than that for which it was prescribed.
  3. Patients should report any signs of adverse reactions to their physician.
  4. Protect Aczone® Gel, 5%, from freezing.
  5. See Patient Labeling for additional information on safety, efficacy, general use, and storage of Aczone® Gel, 5%.

------Cut Here ✂ --------------------------------------------------------------------------------------

FDA-Approved Patient Labeling

Aczone® (dapsone) Gel 5%

Read this important information before you start using Aczone® (AK-zôn) Gel and each time you refill your prescription. There may be new information that you need to know. This summary is not meant to take the place of your doctor's advice. If you have any questions or want more information about Aczone® Gel, ask your doctor or pharmacist.

What is Aczone® Gel?

Aczone® Gel is a prescription medicine used on your skin (topical) to treat acne in people 12 years and older.

Aczone® Gel has not been studied in children under 12 years of age.

Who should not use Aczone® Gel?

Do not use Aczone® Gel if you are allergic to any of the ingredients in Aczone® Gel or if you are younger than 12 years of age.

Active ingredient: dapsone.
Inactive ingredients: Carbomer homopolymer type C, diethylene glycol monoethyl ether (DGME), methylparaben, sodium hydroxide, and purified water.

What should I tell my doctor before using Aczone® Gel?

Tell your doctor about all of your medical conditions, including if you:

  • are pregnant or planning to become pregnant. It is not known if Aczone® Gel may harm your unborn baby. You and your doctor will need to decide if Aczone® is right for you.
  • are breastfeeding. Aczone® Gel passes into your milk and may harm your baby. You should choose either to use Aczone® Gel, or breastfeed, but not both. Talk to your doctor about the best way to feed your baby while using Aczone® Gel.
  • have glucose-6-phosphate dehydrogenase deficiency.

Tell your doctor about all the medicines you are taking including prescription and nonprescription medicines, vitamins and herbal supplements. Especially, tell your doctor if you are using any other medicines applied to the skin, such as acne medicines with benzoyl peroxide.

How do I use Aczone® Gel?

  • Use Aczone® Gel exactly as prescribed by your doctor. Aczone® Gel is usually used on your affected skin twice a day, once in the morning and once in the evening.
  • Wash the areas of your skin where you will apply Aczone® Gel. Gently pat your skin dry with a clean towel.
  • Apply a thin layer of Aczone® Gel to the areas of your skin that have acne. A pea-sized amount of Aczone® Gel will usually be enough.
  • Rub the medicine in gently and completely.
  • Make sure to put the cap back on the Aczone® Gel tube. Close it tightly.
  • Wash your hands after applying Aczone® Gel.
  • Keep Aczone® Gel away from your mouth and eyes. Do not swallow Aczone® Gel. If you swallow Aczone® Gel, call your doctor or poison control center right away.
  • If your acne does not get better after using Aczone® Gel for 12 weeks, talk to your doctor about other treatments for acne.

What are the possible side effects of Aczone® Gel?

Like all medicines, Aczone® Gel can cause some side effects. The most common side effects of Aczone® Gel are dryness, redness, oiliness and peeling of the skin being treated.

When the active ingredient of Aczone® Gel (called dapsone) is taken orally as a pill, it has been related to the abnormal breakdown of red blood cells (hemolytic anemia). If you have glucose-6-phosphate dehydrogenase deficiency, you may have a greater risk for lowering your hemoglobin level. However, using Aczone® Gel on the skin is not expected to put enough dapsone in the blood to cause clinical symptoms of hemolytic anemia. You are advised to be alert for signs and symptoms suggestive of this type of anemia (sudden onset of: back pain, breathlessness, tiredness/weakness with daily activities, dark-brown urine, high fever and yellow or pale skin). If you experience these signs and symptoms, stop use and call your doctor immediately.

Use of benzoyl peroxide together with Aczone® Gel at the same time may cause your skin to temporarily turn yellow or orange at the site of application.

This is not a complete list of all the possible side effects. Call your doctor if you have any side effects that do not go away or bother you. If you have any questions, ask your doctor or pharmacist.

How should I store Aczone® Gel?

Store Aczone® Gel at room temperature 68º to 77ºF. Do not freeze Aczone® Gel.

Keep Aczone® Gel out of the reach of children less than 12 years of age.

Where can I find more information about Aczone® Gel?

If you have any questions or want more information about Aczone® Gel, ask your doctor or pharmacist. Your doctor or pharmacist can also give you a copy of the Aczone® Gel Package Insert written for health professionals. Ask them to explain anything you do not understand.

You may call 1-800-433-8871 to obtain more information about Aczone® Gel.

Aczone® (dapsone) Gel, 5%

© 2013 Allergan, Inc., Irvine, CA 92612, U.S.A.
® marks owned by Allergan, Inc.
Patented. See: www.allergan.com/products/patent_notices
Made in the U.S.A.

72205US13

NDC 0023-3670-90

Aczone®
(dapsone) gel, 5%

FOR TOPICAL USE ONLY

ALLERGAN®

Rx only

90 g

Aczone 
dapsone gel
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0023-3670
Route of Administration TOPICAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
dapsone (dapsone) dapsone 50 mg  in 1 g
Inactive Ingredients
Ingredient Name Strength
carbomer homopolymer type C  
diethylene glycol monoethyl ether  
methylparaben  
sodium hydroxide  
water  
Packaging
# Item Code Package Description
1 NDC:0023-3670-03 15 TUBE in 1 CARTON
1 3 g in 1 TUBE
2 NDC:0023-3670-30 1 TUBE in 1 CARTON
2 30 g in 1 TUBE
3 NDC:0023-3670-60 1 TUBE in 1 CARTON
3 60 g in 1 TUBE
4 NDC:0023-3670-90 1 TUBE in 1 CARTON
4 90 g in 1 TUBE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA021794 06/24/2009
Labeler - Allergan, Inc. (144796497)
Establishment
Name Address ID/FEI Operations
Allergan, Inc. 362898611 MANUFACTURE(0023-3670)
Revised: 03/2013
 
Allergan, Inc.
Hide
(web1)